Post-earnings recap
Reported
Thu, Jul 30, 2026
EPS actual
$0.56
EPS est.
$0.36
EPS surprise
+53.85%
1-day move
+7.99%
Baxter International's earnings report showed a positive surprise in EPS, which contributed to a strong stock reaction, with shares rising nearly 8%. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.56 | $0.54 | +3.85% |
| Revenue | N/A | $2.9B | N/A |
No transcript is on record, so the analysis is based solely on numerical results.
Baxter International Inc. is a healthcare company that develops and provides a range of medical devices and equipment. With a focus on improving patient care, Baxter plays a crucial role in the healthcare sector, particularly in areas like renal care and surgical products.
Last quarter
In Q1 2026, Baxter reported an EPS of $0.36, exceeding expectations by 15.38%. The stock reacted positively, gaining 4.02% the following day.
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+11.39%
Avg 1-day reaction
-4.74%
Analysts expect Baxter to report an EPS of $0.54 and revenue of $2.9 billion for Q2 2026. The market is looking for signs of recovery and growth following mixed results in previous quarters.
Bull case
If Baxter meets or exceeds EPS and revenue expectations, it could signal a turnaround in performance, boosting investor confidence and potentially leading to a significant stock price increase.
Bear case
Conversely, if Baxter falls short of expectations, especially after a recent positive surprise, it could raise concerns about ongoing operational challenges and lead to a sharp decline in stock price.
Key metrics to watch
EPS
$0.54Earnings per share is a key indicator of profitability and will show how well Baxter is managing costs and generating income.
Revenue
$2.9BTotal revenue gives insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will EPS exceed the consensus estimate of $0.54?
A beat on EPS could indicate improved operational efficiency and stronger demand for Baxter's products, which is critical for investor confidence.
Q2
What are the revenue growth trends compared to the expected $2.9 billion?
Revenue performance will provide insights into market demand and the effectiveness of Baxter's sales strategies, influencing future growth projections.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.0%
Why consensus could be wrong
The consensus may underestimate Baxter's recovery potential, as recent operational improvements and product demand could lead to better-than-expected results.
Supporting evidence
Baxter's recent EPS surprise of +15.38% indicates a potential trend of improved performance.
Options pricing suggests a lower expected move compared to historical averages, indicating a possible undervaluation of volatility.
The company's focus on innovation in healthcare equipment may drive stronger sales than analysts anticipate.
Key risk
If revenue growth exceeds $2.9 billion, it could significantly shift market sentiment and expectations.
Pre-commit to what would confirm each case.
This quarter's results are critical as they will reflect Baxter's ability to navigate recent challenges and capitalize on market opportunities.
Bull confirmed if
An EPS of $0.54 or higher, along with revenue exceeding $2.9 billion, would confirm a positive outlook for the company.
Bear confirmed if
An EPS below $0.50 or revenue falling short of $2.8 billion would raise significant concerns about the company's performance.
What the market is pricing for the move.
Implied Move
±6.74%
Historical Avg
±9.9%
The options market is pricing in a moderate move around the earnings report, indicating uncertainty about the results.
Options are pricing ±6.7% while BAX has averaged ±9.9% over the last 8 prints — setup is pricing cheap.
ATM IV
0.5%
30d HV
40.0%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
110.22%
of float
Insider
0.34%
of float
Holders
951
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
81,842,105 sh · $2.0B
15.83%
3.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Baxter beats expectations, history suggests a potential stock increase of around 0.59%, confirming a positive trend in performance.
In line / cautious
If results are in line with expectations, the stock may react moderately, reflecting cautious optimism from investors.
Miss
A miss on earnings could lead to a decline of about 14.10%, as seen in past performance when expectations were not met.
The lines on the call that would change the story.
Pzena Investment Management LLC
65,295,393 sh · $1.6B
12.63%
1.2%
Dodge & Cox Inc.
58,386,345 sh · $1.4B
11.29%
2.0%
FMR, LLC
53,913,831 sh · $1.3B
10.43%
16.5%
Vanguard Capital Management LLC
33,754,280 sh · $809.1M
6.53%
0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.